search
Back to results

Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects

Primary Purpose

Dermatitis, Phototoxic

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Butenafine HCl 1% (BAY1896425)
Sponsored by
Bayer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dermatitis, Phototoxic

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Participants must have been between the ages of 18 and 60 years;
  • Participants must have been lightly pigmented (Fitzpatrick skin phototypes I, II, III);
  • Participants must have been in good general health as determined by the subject's medical history;
  • Participants must have been willing to avoid tanning bed usage and additional sun exposure during the trial and follow-up period;
  • Participants must have been willing to refrain from using any new topical products during the trial;
  • Participants must have been able and willing to cooperate with the Investigator and research staff, to have test materials applied according to protocol, and to complete the full course of the trial;
  • Participants must have been willing to report any medications taken during the trial and refrain from taking any medications during the trial that might produce photoreactions;
  • If female, participants must produce a negative urine pregnancy test prior to the initiation and also at the completion of the trial.

Exclusion Criteria:

  • Participants must not have had visible sunburn;
  • Participants must not have had a history of sun hypersensitivity/photosensitivity, or photosensitive dermatoses;
  • Participants must not have had a history of allergies or sensitivities to cosmetics, toiletries, or any dermatological products;
  • Participants must not have recently used any systemic or topical drugs which could have caused a photoreaction or may have interfered with the trial;
  • Participants must not have had any known skin conditions that might interfere with the proper conduct of the trial;
  • Participants must not have had scars, moles, excessive hair, or other blemishes over the mid or lower back which might have interfered with the test or the grading of the test sites;
  • Participants must not have had significant history of internal disease that may have interfered with the evaluation of the test material as determined by the Investigator;
  • Participants must not have been pregnant, planning pregnancy, or nursing a child during the trial period;
  • Participants must not have used a tanning bed or other artificial tanning lights within the past two months;
  • Participants must not have participated in a patch test involving the back within four weeks prior to the start of the trial;
  • Participants must not have concurrently participated in any other clinical or consumer test;
  • Participants must not have had other conditions considered by the Investigator as sound reasons for disqualification from enrollment into the trial.

Sites / Locations

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Phototoxicity reaction test

Arm Description

Participants received approximately 60 μl of Butenafine HCl 1% on the treated irradiated test site followed by Ultraviolet Radiation (UV) irradiation and to the treated non-irradiated test site without UV irradiation. Participants also had two more test sites, the untreated irradiated control site without Butenafine HCl 1% followed by UV irradiation and the untreated non-irradiated control site without Butenafine HCl 1% or UV irradiation. All test sites were evaluated for erythema on the following day. Afterwards, participants received same procedure on all 4 test sites, and evaluation of the test sites occurred at 24 hours and 48 hours post-irradiation.

Outcomes

Primary Outcome Measures

Phototoxic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score
Evaluation of the test sites after irradiation used following scoring system: score 0=Normal skin; score 1=Faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=Moderate to intense redness with well defined margins; score 3=Redness plus well defined edema; score 4=Redness plus papules, vesicles, or ulceration. All four test sites were evaluated for gross changes according to the Erythemal Scoring Scale and if necessary the Additional Scoring system immediately before irradiation, 24 hours after irradiation, and 48 hours after irradiation (3 different time points), thus for each type of test site (i.e. treated irradiated test site), a total of 87 test sites with scores were collected (i.e., 29 participants *3 time points = 87 sites).

Secondary Outcome Measures

Development of Erythema on the Treated Non-irradiated Test Sites, Which Would Indicate Irritant Contact Dermatitis and a Pre-existing Allergic Contact Dermatitis
Evaluation of the test sites after irradiation used following scoring system: score 0=Normal skin; score 1=Faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=Moderate to intense redness with well defined margins; score 3=Redness plus well defined edema; score 4=Redness plus papules, vesicles, or ulceration. All four test sites were evaluated for gross changes according to the Erythemal Scoring Scale and if necessary the Additional Scoring system immediately before irradiation, 24 hours after irradiation, and 48 hours after irradiation (3 different time points), thus for each type of test site (i.e. treated irradiated test site), a total of 87 test sites with scores were collected (i.e., 29 participants *3 time points = 87 sites).

Full Information

First Posted
August 26, 2020
Last Updated
October 21, 2020
Sponsor
Bayer
search

1. Study Identification

Unique Protocol Identification Number
NCT04531527
Brief Title
Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects
Official Title
HT201308- Human Phototoxicity Test
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
June 24, 2013 (Actual)
Primary Completion Date
June 28, 2013 (Actual)
Study Completion Date
June 28, 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bayer

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In this study researchers want to gather information about the potential of Antifungal Cream V61-044 containing Trolamine to produce a phototoxic reaction on the skin. A phototoxic reaction is an irritant reaction of the skin to ultra violet light. In order to find this out the study drug will be applied to the skin of healthy human subjects. By using a solar simulator to generate a UV spectrum similar to that of sunlight the potential of the study drug to produce a superficial reddening of the skin will be measured.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dermatitis, Phototoxic

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
32 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Phototoxicity reaction test
Arm Type
Experimental
Arm Description
Participants received approximately 60 μl of Butenafine HCl 1% on the treated irradiated test site followed by Ultraviolet Radiation (UV) irradiation and to the treated non-irradiated test site without UV irradiation. Participants also had two more test sites, the untreated irradiated control site without Butenafine HCl 1% followed by UV irradiation and the untreated non-irradiated control site without Butenafine HCl 1% or UV irradiation. All test sites were evaluated for erythema on the following day. Afterwards, participants received same procedure on all 4 test sites, and evaluation of the test sites occurred at 24 hours and 48 hours post-irradiation.
Intervention Type
Drug
Intervention Name(s)
Butenafine HCl 1% (BAY1896425)
Other Intervention Name(s)
Antifungal Cream V61-044 containing Trolamine
Intervention Description
Approximately 60 μl of Butenafine HCl 1% applied twice to the treated irradiated site and to the treated non-irradiated site for a total application of 240 μl of Butenafine HCl 1%.
Primary Outcome Measure Information:
Title
Phototoxic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score
Description
Evaluation of the test sites after irradiation used following scoring system: score 0=Normal skin; score 1=Faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=Moderate to intense redness with well defined margins; score 3=Redness plus well defined edema; score 4=Redness plus papules, vesicles, or ulceration. All four test sites were evaluated for gross changes according to the Erythemal Scoring Scale and if necessary the Additional Scoring system immediately before irradiation, 24 hours after irradiation, and 48 hours after irradiation (3 different time points), thus for each type of test site (i.e. treated irradiated test site), a total of 87 test sites with scores were collected (i.e., 29 participants *3 time points = 87 sites).
Time Frame
Immediately before irradiation, 24 hours after irradiation, and 48 hours after irradiation
Secondary Outcome Measure Information:
Title
Development of Erythema on the Treated Non-irradiated Test Sites, Which Would Indicate Irritant Contact Dermatitis and a Pre-existing Allergic Contact Dermatitis
Description
Evaluation of the test sites after irradiation used following scoring system: score 0=Normal skin; score 1=Faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=Moderate to intense redness with well defined margins; score 3=Redness plus well defined edema; score 4=Redness plus papules, vesicles, or ulceration. All four test sites were evaluated for gross changes according to the Erythemal Scoring Scale and if necessary the Additional Scoring system immediately before irradiation, 24 hours after irradiation, and 48 hours after irradiation (3 different time points), thus for each type of test site (i.e. treated irradiated test site), a total of 87 test sites with scores were collected (i.e., 29 participants *3 time points = 87 sites).
Time Frame
Immediately before irradiation, 24 hours after irradiation, and 48 hours after irradiation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Participants must have been between the ages of 18 and 60 years; Participants must have been lightly pigmented (Fitzpatrick skin phototypes I, II, III); Participants must have been in good general health as determined by the subject's medical history; Participants must have been willing to avoid tanning bed usage and additional sun exposure during the trial and follow-up period; Participants must have been willing to refrain from using any new topical products during the trial; Participants must have been able and willing to cooperate with the Investigator and research staff, to have test materials applied according to protocol, and to complete the full course of the trial; Participants must have been willing to report any medications taken during the trial and refrain from taking any medications during the trial that might produce photoreactions; If female, participants must produce a negative urine pregnancy test prior to the initiation and also at the completion of the trial. Exclusion Criteria: Participants must not have had visible sunburn; Participants must not have had a history of sun hypersensitivity/photosensitivity, or photosensitive dermatoses; Participants must not have had a history of allergies or sensitivities to cosmetics, toiletries, or any dermatological products; Participants must not have recently used any systemic or topical drugs which could have caused a photoreaction or may have interfered with the trial; Participants must not have had any known skin conditions that might interfere with the proper conduct of the trial; Participants must not have had scars, moles, excessive hair, or other blemishes over the mid or lower back which might have interfered with the test or the grading of the test sites; Participants must not have had significant history of internal disease that may have interfered with the evaluation of the test material as determined by the Investigator; Participants must not have been pregnant, planning pregnancy, or nursing a child during the trial period; Participants must not have used a tanning bed or other artificial tanning lights within the past two months; Participants must not have participated in a patch test involving the back within four weeks prior to the start of the trial; Participants must not have concurrently participated in any other clinical or consumer test; Participants must not have had other conditions considered by the Investigator as sound reasons for disqualification from enrollment into the trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bayer Study Director
Organizational Affiliation
Bayer
Official's Role
Study Director
Facility Information:
City
Fairfield
State/Province
New Jersey
ZIP/Postal Code
07004
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Links:
URL
https://clinicaltrials.bayer.com/
Description
Click here to find results for studies related to Bayer Healthcare products.

Learn more about this trial

Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects

We'll reach out to this number within 24 hrs